https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease.
DESCRIPTION:
Condition: Parkinson Disease
Interventions: Drug: Active drug: pimavanserin 17mg (2 strength tablets); Drug: Placebo: 2 tablets containing same excipients except active compound; Behavioral: Assessment of severity of ICD (impulse control disorders); Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Behavioral: Assessment of quality of life; Behavioral: Assessment of depression; Behavioral: Assessment of cognition; Behavioral: Assessment of severity of Parkinson Disease; Procedure: Blood analysis; Procedure: Cardiac monitoring
Sponsor: University Hospital, Strasbourg, France
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03947216
FIRST POSTED:
Mon, 13 May 2019 12:00:00 EDT
LAST UPDATE POSTED:
05/13/19 07:43AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst
